Angiogenesis and non-small cell lung cancer

被引：95
|
作者：
Cox, G
Jones, JL
Walker, RA
Steward, WP
O'Byrne, KJ
机构：
[1] Leicester Royal Infirm, Univ Dept Med Oncol, Leicester LE1 5WW, Leics, England
[2] Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England
[3] Glenfield Gen Hosp, Dept Pathol, Leicester LE3 9QP, Leics, England
来源：
LUNG CANCER | 2000年 / 27卷 / 02期
关键词：
angiogenesis; matrix metalloproteinases; growth factors; apoptosis; non-small cell lung cancer;
D O I：
10.1016/S0169-5002(99)00096-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is the commonest cause of cancer death in the western world. Recent evidence suggests that angiogenesis is related to poor prognosis in many solid tumours including non-small cell lung cancer. Angiogenesis is controlled by a complex interaction between growth and apoptotic factors, proteases and adhesion molecules. The angiogenic process may prove a target for novel therapies such as matrix metalloproteinase inhibitors, growth factor antisense RNA, growth factor. receptor antagonists and naturally occurring antiangiogenic peptides. These agents may be used alone ol in combination with traditional chemotherapy, radiotherapy and surgery. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码：81 / 100
页数：20
相关论文
共 50 条
  • [31] Relationship between cancer cell proliferation, tumour angiogenesis and 201TI uptake in non-small cell lung cancer
    Fujita, Seigo
    Nagamachi, Shigeki
    Nishii, Ryuichi
    Wakamatsu, Hideyuki
    Futami, Shigemi
    Tamura, Shozo
    Matsuzaki, Yasunori
    Onizuka, Toshio
    Hatakeyama, Kinta
    Asada, Yujiro
    NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (12) : 989 - 997
  • [32] Oligoprogression in Non-Small Cell Lung Cancer
    Harada, Daijiro
    Takigawa, Nagio
    CANCERS, 2021, 13 (22)
  • [33] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [34] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
  • [35] Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
    Bremnes, RM
    Camps, C
    Sirera, R
    LUNG CANCER, 2006, 51 (02) : 143 - 158
  • [36] Allelotype of non-small cell lung cancer
    Neville, EM
    Stewart, MP
    Swift, A
    Liloglou, T
    Ross, H
    Gosney, JR
    Donnelly, RJ
    Field, JK
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (03) : 533 - 539
  • [37] Non-small cell lung cancer in China
    Chen, Peixin
    Liu, Yunhuan
    Wen, Yaokai
    Zhou, Caicun
    CANCER COMMUNICATIONS, 2022, 42 (10) : 937 - 970
  • [38] Necitumumab for non-small cell lung cancer
    Greillier, Laurent
    Tomasini, Pascale
    Bariesi, Fabrice
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (08) : 1231 - 1239
  • [39] Staging of non-small cell lung cancer
    Heigener, D. F.
    Deppermann, K. -M.
    Sebastian, M.
    Reck, M.
    ONKOLOGE, 2011, 17 (08): : 679 - 683
  • [40] Anthacyclines in non-small cell lung cancer
    Pronzato, P
    Vigani, A
    Tognoni, A
    Vaira, F
    Canessa, P
    LUNG CANCER, 2001, 34 : S57 - S59
12345